Celldex advances cancer drug candidate

Mass High Tech: The Journal of New England Technology

Celldex Therapeutics, Inc. (NASDAQ: CLDX) has announced positive Phase 1 trial results for its experimental vaccine for solid tumors, in combination with two approved drugs.